Acceptability of and treatment preferences for recurrent bacterial vaginosis—Topical lactic acid gel or oral metronidazole antibiotic: Qualitative findings from the VITA trial
Autoři:
Jocelyn Anstey Watkins aff001; Jonathan D. C. Ross aff002; Sukhwinder Thandi aff003; Clare Brittain aff003; Joe Kai aff004; Frances Griffiths aff001
Působiště autorů:
Warwick Medical School, University of Warwick, Coventry, England, United Kingdom
aff001; University Hospitals Birmingham NHS Foundation Trust, Birmingham, England, United Kingdom
aff002; Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, England, United Kingdom
aff003; Division of Primary Care, University of Nottingham, Nottingham, England, United Kingdom
aff004; Centre for Health Policy, University of the Witwatersrand, Johannesburg, South Africa
aff005
Vyšlo v časopise:
PLoS ONE 14(11)
Kategorie:
Research Article
doi:
https://doi.org/10.1371/journal.pone.0224964
Souhrn
Background
Bacterial vaginosis (BV) is associated with an elevated vaginal pH and the presence of abnormal offensive discharge. It is common, often recurrent, and the most effective treatment regimen is unknown. ‘Metronidazole Versus lactic acId for Treating bacterial vAginosis’ (VITA) is a UK-based randomised controlled trial assessing clinical and cost-effectiveness of topical lactic acid gel compared to oral metronidazole antibiotic for treating second and subsequent BV episodes. Few BV trials report on women’s preferences for treatment in the context of their own experiences.
Method
This qualitative study investigated the acceptability and tolerability of the two treatments. During the trial, semi-structured telephone interviews were undertaken between January—May 2018. A total of 33 women diagnosed with BV were consecutively sampled then interviewed from six sites across England. Thematic analysis was guided by the acceptability of health interventions framework. Potential causes of BV and its impact on women’s lives were explored in addition to women’s treatment preference and perceived treatment effectiveness.
Results
Although women felt antibiotics treat BV effectively, and were associated with longer time periods between episodes, they generally preferred using the lactic acid gel because of ease of use, once daily application and less side-effects. Women would recommend the lactic acid gel to others for mild cases of BV but to take antibiotics when more severe. The risk of antibiotic drug resistance was a common concern. Self-help medicating or self-decision to not treat was also evident due to prior experience of poor outcomes from treatment. Triggers of BV were attributed to personal hygiene habits–soaps used to wash the vagina and sexual practices such as unprotected sex.
Conclusion
Acceptability and preference for topical lactic acid gel or oral metronidazole tablets in the treatment of recurrent BV was affected by personal choice relating to affective attitude, burden, ethicality, intervention coherence, opportunity costs, and self-efficacy. These differed depending on ease of use, tolerability and past experiences, but not necessarily based on perceived drug effectiveness. Knowledge of a patient preference for topical lactic acid gel therapy despite lower perceived effectiveness may be useful for clinicians when making treatment decisions.
Klíčová slova:
Antibiotic resistance – Antibiotics – Behavior – Drug therapy – Jaw – Lactic acid – Bacterial vaginosis
Zdroje
1. Bradshaw CS, Brotman RM. Making inroads into improving treatment of bacterial vaginosis–striving for long-term cure. BMC infectious diseases. 2015;15(1):292.
2. Forsum U, Holst E, Larsson P-G, Vasquez A, Jakobsson T, Mattsby‐Baltzer I. Bacterial vaginosis–a microbiological and immunological enigma. Apmis. 2005;113(2):81–90. doi: 10.1111/j.1600-0463.2005.apm1130201.x 15723682
3. Turovskiy Y, Noll KS, Chikindas ML. The aetiology of bacterial vaginosis. Journal of applied microbiology. 2011;110(5):1105–28. doi: 10.1111/j.1365-2672.2011.04977.x 21332897
4. Wilson J. Managing recurrent bacterial vaginosis. Sexually transmitted infections. 2004;80(1):8–11. doi: 10.1136/sti.2002.002733 14755028
5. Hull CE, McLellan AR. Acute and Recurrent Bacterial Vaginosis. Clinician Reviews. 2016;44.
6. O'brien RF. Bacterial vaginosis: many questions-any answers? Current opinion in pediatrics. 2005;17(4):473–9. doi: 10.1097/01.mop.0000170516.35272.45 16012258
7. Machado D, Castro J, Palmeira-de-Oliveira A, Martinez-de-Oliveira J, Cerca N. Bacterial Vaginosis Biofilms: Challenges to Current Therapies and Emerging Solutions. 2016.
8. Phillip Hay SP, David Daniels. UK National Guideline for the management of Bacterial Vaginosis 2012. UK: Clinical Effectiveness Group British Association for Sexual Health and HIV; 2012.
9. Ma L, Su J, Su Y, Sun W, Zeng Z. Probiotics administered intravaginally as a complementary therapy combined with antibiotics for the treatment of bacterial vaginosis: a systematic review protocol. BMJ open. 2017;7(10):e019301. doi: 10.1136/bmjopen-2017-019301 29038188
10. Hemmerling A, Harrison W, Schroeder A, Park J, Korn A, Shiboski S, et al. Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sexually transmitted diseases. 2010;37(12):745–50. doi: 10.1097/OLQ.0b013e3181e50026 20644497
11. Mogha KV, Prajapati JB. Evaluation of probiotic cream by in-vitro tests for treatment of bacterial vaginosis conditions. Reviews in Medical Microbiology. 2017;28(1):19–25.
12. NICE. UK National Guideline for the management of Bacterial Vaginosis 2012: National Institue for Health and Care Excellence 2012 [Available from: https://www.evidence.nhs.uk/search?q=bacterial+vaginosis.
13. Armitage C. Management of Vaginal Discharge. Women's Health in Primary Care. 2017:37.
14. Devaux S, Castela A, Archier E, Gallini A, Joly P, Misery L, et al. Adherence to topical treatment in psoriasis: a systematic literature review. Journal of the European Academy of Dermatology and Venereology. 2012;26:61–7. doi: 10.1111/j.1468-3083.2012.04525.x 22512682
15. Kazdin AE. Acceptability of alternative treatments for deviant child behavior. Journal of Applied Behavior Analysis. 1980;13(2):259–73. doi: 10.1901/jaba.1980.13-259 7380752
16. Miltenberger RG. Assessment of treatment acceptability: A review of the literature. Topics in Early Childhood Special Education. 1990;10(3):24–38.
17. Barbosa CD, Balp M-M, Kulich K, Germain N, Rofail D. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient preference and adherence. 2012;6:39. doi: 10.2147/PPA.S24752 22272068
18. Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: an overview of reviews and development of a theoretical framework. BMC health services research. 2017;17(1):88. doi: 10.1186/s12913-017-2031-8 28126032
19. Bilardi JE, Walker S, Temple-Smith M, McNair R, Mooney-Somers J, Bellhouse C, et al. The burden of bacterial vaginosis: women’s experience of the physical, emotional, sexual and social impact of living with recurrent bacterial vaginosis. PloS one. 2013;8(9):e74378. doi: 10.1371/journal.pone.0074378 24040236
20. ISRCTN. Metronidazole versus lactic acId for treating bacterial vaginosis ISRCTN14161293 registry BMC Springer Nature 2019 [Available from: https://doi.org/10.1186/ISRCTN14161293.
21. Lindsay Armstrong-Buisseret CB, David Miruna, Dean Gillian, Griffiths Frances, Hepburn Trish, Jackson Louise, Kai Joe, Montgomery Alan, Roberts Tracy, Thandi Sukhwinder and Ross Jonathan D. C. Protocol has been submitted—Metronidazole versus lactic acid for treating bacterial vaginosis (VITA): protocol for a randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis. Trials. 2019;in submission
22. O’Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Academic Medicine. 2014;89(9):1245–51. doi: 10.1097/ACM.0000000000000388 24979285
23. Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology. 2006;3(2):77–101.
24. Bilardi JE, Walker SM, Temple-Smith MJ, McNair RP, Mooney-Somers J, Vodstrcil LA, et al. Women view key sexual behaviours as the trigger for the onset and recurrence of bacterial vaginosis. PloS one. 2017;12(3):e0173637. doi: 10.1371/journal.pone.0173637 28278277
25. Adolfsson A, Hagander A, Mahjoubipour F, Larsson P-G. How Vaginal Infections Impact Women's Everyday Life: Women's Lived Experiences of Bacterial Vaginosis and Recurrent Vulvovaginal Candidiasis. Advances in Sexual Medicine. 2017;7(1):1–19.
26. Payne SC, Cromer PR, Stanek MK, Palmer AA. Evidence of African‐American women's frustrations with chronic recurrent bacterial vaginosis. Journal of the American Academy of Nurse Practitioners. 2010;22(2):101–8. doi: 10.1111/j.1745-7599.2009.00474.x 20132368
27. McGowan I, Gomez K, Bruder K, Febo I, Chen BA, Richardson BA, et al. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel®) in sexually active young women (MTN-004). AIDS (London, England). 2011;25(8):1057.
28. Coggins C, Blanchard K, Alvarez F, Brache V, Weisberg E, Kilmarx P, et al. Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sexually Transmitted Infections. 2000;76(6):480–3. doi: 10.1136/sti.76.6.480 11221133
Článek vyšel v časopise
PLOS One
2019 Číslo 11
- S diagnostikou Parkinsonovy nemoci může nově pomoci AI nástroj pro hodnocení mrkacího reflexu
- Proč při poslechu některé muziky prostě musíme tančit?
- Je libo čepici místo mozkového implantátu?
- Chůze do schodů pomáhá prodloužit život a vyhnout se srdečním chorobám
- Pomůže v budoucnu s triáží na pohotovostech umělá inteligence?
Nejčtenější v tomto čísle
- A daily diary study on maladaptive daydreaming, mind wandering, and sleep disturbances: Examining within-person and between-persons relations
- A 3’ UTR SNP rs885863, a cis-eQTL for the circadian gene VIPR2 and lincRNA 689, is associated with opioid addiction
- A substitution mutation in a conserved domain of mammalian acetate-dependent acetyl CoA synthetase 2 results in destabilized protein and impaired HIF-2 signaling
- Molecular validation of clinical Pantoea isolates identified by MALDI-TOF
Zvyšte si kvalifikaci online z pohodlí domova
Všechny kurzy